Iqvia Holdings Inc (NYSE:IQV) insider Ari Bousbib sold 46,080 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $101.79, for a total value of $4,690,483.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Ari Bousbib also recently made the following trade(s):
- On Wednesday, November 1st, Ari Bousbib sold 46,080 shares of Iqvia stock. The stock was sold at an average price of $108.14, for a total value of $4,983,091.20.
- On Monday, October 2nd, Ari Bousbib sold 46,080 shares of Iqvia stock. The stock was sold at an average price of $94.91, for a total value of $4,373,452.80.
Shares of Iqvia Holdings Inc (NYSE:IQV) opened at $100.92 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.22 and a debt-to-equity ratio of 1.29. Iqvia Holdings Inc has a 12 month low of $74.73 and a 12 month high of $110.67. The company has a market capitalization of $21,290.00, a PE ratio of 23.06, a price-to-earnings-growth ratio of 1.66 and a beta of 0.61.
Iqvia (NYSE:IQV) last released its quarterly earnings results on Thursday, October 26th. The medical research company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.05. Iqvia had a return on equity of 12.60% and a net margin of 0.58%. The company had revenue of $2.02 billion during the quarter, compared to analysts’ expectations of $2.01 billion. During the same period last year, the business posted $1.00 earnings per share. The firm’s revenue was up 77.6% compared to the same quarter last year. equities research analysts predict that Iqvia Holdings Inc will post 4.62 EPS for the current year.
A number of equities research analysts recently weighed in on the company. Mizuho cut Iqvia from a “buy” rating to a “neutral” rating in a research note on Thursday, November 9th. BidaskClub cut Iqvia from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 11th. KeyCorp restated a “buy” rating and set a $100.00 price objective on shares of Iqvia in a research note on Sunday, September 24th. Robert W. Baird restated a “hold” rating and set a $98.00 price objective on shares of Iqvia in a research note on Monday, October 9th. Finally, Zacks Investment Research cut Iqvia from a “buy” rating to a “hold” rating in a research note on Friday, November 3rd. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $105.23.
TRADEMARK VIOLATION NOTICE: “Insider Selling: Iqvia Holdings Inc (IQV) Insider Sells $4,690,483.20 in Stock” was reported by Stock Observer and is the sole property of of Stock Observer. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.thestockobserver.com/2017/12/08/insider-selling-iqvia-holdings-inc-iqv-insider-sells-4690483-20-in-stock.html.
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Iqvia Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.